SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-012666
Filing Date
2022-08-08
Accepted
2022-08-08 17:14:09
Documents
66
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20220630x10q.htm   iXBRL 10-Q 2104704
2 EX-31.1 tbph-20220630xex31d1.htm EX-31.1 13463
3 EX-31.2 tbph-20220630xex31d2.htm EX-31.2 14252
4 EX-32 tbph-20220630xex32.htm EX-32 16308
  Complete submission text file 0001558370-22-012666.txt   7483739

Data Files

Seq Description Document Type Size
5 EX-101.SCH tbph-20220630.xsd EX-101.SCH 52504
6 EX-101.CAL tbph-20220630_cal.xml EX-101.CAL 54862
7 EX-101.DEF tbph-20220630_def.xml EX-101.DEF 223968
8 EX-101.LAB tbph-20220630_lab.xml EX-101.LAB 444201
9 EX-101.PRE tbph-20220630_pre.xml EX-101.PRE 345378
60 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20220630x10q_htm.xml XML 1205518
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 221145395
SIC: 2834 Pharmaceutical Preparations